Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Single-Wholesaler Distribution Unlikely to Constitute Antimonopoly Law Violation: Expert
August 8, 2022
-
REGULATORY LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
-
BUSINESS Moderna Eyes mRNA Plant in Japan, but Multi-Year Purchase Pact a Must: Local President
August 5, 2022
-
ORGANIZATION Single-Wholesaler Distribution Should Be Redressed from Stable Supply Standpoint: JMA Official
August 4, 2022
-
BUSINESS Trulicity Sales Alliance Deal to Expire by 2022-End: Lilly Japan/Sumitomo
August 4, 2022
-
BUSINESS Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
-
REGULATORY Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
-
REGULATORY Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
-
BUSINESS Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
-
REGULATORY KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
-
REGULATORY New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
-
BUSINESS Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
-
BUSINESS Mochida to Quit Filgrastim Biosimilar as Repeated Price Cuts Made It Unprofitable
July 28, 2022
-
BUSINESS GSK Japan Foresees 5% Annual Growth by 2026: President Lirette
July 28, 2022
-
BUSINESS Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
-
ORGANIZATION Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
-
ORGANIZATION JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
-
BUSINESS BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms
July 26, 2022
-
REGULATORY Japan Confirms 1st Monkeypox Case
July 26, 2022
-
COMMENTARY Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
July 25, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…